Last updated: April 25, 2026
What is taselisib and where does it sit in clinical development?
Taselisib (GDC-0032) is an oral, small-molecule PI3K inhibitor with activity across class I PI3K isoforms. It was developed by Genentech/Roche for cancers with dysregulated PI3K signaling.
Regulatory status (core point for planning):
- No approved indication for taselisib is listed in global regulatory approvals at this time (as of the latest accessible public records in the cited sources). [1]
Clinical development status (termination signal):
- Multiple programs using taselisib have moved into discontinuation phases in public disclosures and publications, consistent with reduced differentiation versus other PI3K pathway agents and/or a risk-return profile that did not support continued late-stage expansion. [2], [3]
What do the latest public signals say about efficacy and tolerability?
Across taselisib’s development, the recurring driver of clinical progression has been balancing pathway efficacy against PI3K-class toxicities (notably hyperglycemia and rash-related AEs), which often constrain dosing intensity.
Evidence from publicly described studies shows that:
- Taselisib demonstrates on-target PI3K pathway pharmacology and measurable antitumor activity signals in subsets, but
- Clinical benefit has been inconsistent across tumor types and combinations,
- Dose-limiting toxicities and class effects have affected dose intensity and continuation for some regimens.
Key published signals include:
- Combination work in solid tumors and biomarker-enriched strategies has produced responses but not durable, broad differentiation sufficient to sustain a single dominant registration path. [2], [3]
- Reported PI3K inhibitor safety patterns are consistent with the class, affecting tolerability and regimen design. [3]
Where does taselisib fit versus the PI3K competitive set?
The PI3K landscape has shifted toward agents and combinations with cleaner benefit-risk and stronger sequencing utility.
Competitive context (planning lens):
- The class is crowded with PI3K inhibitors and downstream pathway agents (AKT/mTOR), with competing programs often backed by stronger phase-to-phase continuation.
- In late-stage oncology, payer adoption depends on demonstrated clinical value in defined lines and combinations. For taselisib, the public record does not show a stabilized late-stage path leading to approval, which directly limits near-term market pull.
Public development and response outcomes in the PI3K class are documented broadly in the clinical literature and drug-profile databases that summarize phase progress and discontinuations. [1], [2], [3]
What is the current development outlook for investors and R&D teams?
For a market projection, the decisive variable is whether taselisib has a credible, funded pathway to approval. The cited public record does not indicate an ongoing, registration-grade late-stage program that would typically anchor a commercialization forecast.
Operational implications:
- Without an approved label, taselisib market sizing depends on either (1) a future resumption of late-stage development with a clear regulatory endgame or (2) a planned acquisition/licensing that re-starts development.
- Publicly available summaries indicate that the program has not progressed to a clear approval outcome. [1]
- Published clinical reports document activity and safety constraints but do not show a consolidated, phase-3-defining efficacy package. [2], [3]
How big could the market be if taselisib re-emerges with a defined indication?
Because taselisib is not approved, any “market projection” must be framed as a scenario model tied to a potential label that would be plausible given its MOA and historical study directions.
Below is a base-case projection framework used for commercialization planning in oncology when a drug lacks approval but has historical clinical evidence. The ranges are driven by:
- PI3K pathway indication size and adoption dynamics,
- the likelihood of competitive displacement,
- probability-adjusted launch timing.
Scenario assumptions for projection
| Parameter |
Base case assumption |
Range used |
| Approval probability in next 5 years |
Low-to-moderate |
5% to 15% |
| Launch timing if approval occurs |
1 to 3 years post-approval |
1 to 3 years |
| Target use pattern |
Combination second-line or later (label-dependent) |
line-specific |
| Annual treated patients at maturity |
modest (competitive class + needs biomarker fit) |
3,000 to 15,000 |
| Price per patient per year (ex-US blended proxy) |
mid–high oncology pricing |
$40k to $120k |
| Peak market share within label |
limited without strong differentiation |
5% to 15% |
Base-case revenue model (US+EU5 blended)
Using the treated-patient and price ranges, a plausible commercial ceiling for a non-differentiated or biomarker-constrained PI3K inhibitor is typically modest relative to major late-stage successes.
Projected annual revenue at peak (probability-adjusted):
- Low case: $20M to $60M
- Base case: $60M to $180M
- High case: $180M to $450M
These values represent revenue after adjusting for (a) approval probability and (b) restrained uptake in a crowded PI3K category. The inputs align with the absence of an approved indication and a historical pattern of discontinuations or non-registration progression described in public summaries. [1], [2], [3]
What would move taselisib from low to high?
For a high-end outcome, taselisib would need one of the following to become evident in credible phase data:
- A biomarker-enriched population where efficacy clearly exceeds comparator PI3K pathway standards
- A tolerability breakthrough enabling durable dosing without regimen interruption
- A partner strategy that locks taselisib into a competitive combination with demonstrated clinical superiority
The public record to date does not show a consolidated pathway to these outcomes in a way that supports a straightforward approval-led market build. [2], [3]
Market projection timeline: what to expect by year
Given taselisib’s lack of approval and the historical discontinuation signal, the schedule is best modeled as an option value rather than a straight-line uptake trajectory.
Probability-adjusted commercial outlook
| Year |
Outcome mode |
Expected market impact |
| 2026 |
No approval; monitoring possible renewals |
near-zero to $10M |
| 2027 |
potential restart or partnering announcement window |
$5M to $40M |
| 2028 |
if a registration-grade program restarts, early market relevance |
$10M to $80M |
| 2029 |
possible label if successful |
$30M to $150M |
| 2030 |
peak-building year post-approval (if approved) |
$60M to $180M |
These are probability-adjusted estimates, reflecting that an approval outcome is not established in the public regulatory record. [1]
Commercial risks that cap uptake
Key risks tied to the drug class
- Class toxicities can constrain dosing and reduce adherence to combination regimens. [3]
- Competitive displacement in PI3K signaling affects payer willingness to adopt a PI3K agent that lacks clear superiority.
- Biomarker fit may limit eligible population size depending on assay availability and cutoffs used in labeling.
Key risks tied specifically to taselisib’s record
- Lack of an approved indication in public regulatory sources keeps the addressable commercial ceiling low until a label exists. [1]
- Published clinical progress does not show a unified, late-stage-defining benefit-risk package. [2], [3]
Key Takeaways
- Taselisib is an oral PI3K inhibitor (GDC-0032) with no approved indication in the public regulatory record. [1]
- The public clinical literature shows on-target PI3K activity and activity signals, but does not support a clear, consolidated registration path that would anchor commercialization. [2], [3]
- Market projection is therefore dominated by probability-adjusted scenarios: peak annual revenue (US+EU5 blended) plausibly lands in the $60M to $180M base case range, with a higher ceiling up to about $450M only under strong differentiation or a biomarker-defined, tolerability-optimized label.
- Near-term market impact through 2027 is expected to be minimal unless partnering or re-initiation of a registration-grade program becomes public.
FAQs
-
Is taselisib approved anywhere?
No approved indication is reflected in the cited public regulatory summaries. [1]
-
What is taselisib’s mechanism of action?
It is a class I PI3K inhibitor targeting dysregulated PI3K signaling in cancers. [2]
-
Why is PI3K inhibitor commercialization difficult?
Class toxicities and dosing constraints often limit tolerability and combination intensity, affecting real-world uptake and trial continuation. [3]
-
What patient population would likely matter most for taselisib?
A biomarker-enriched population aligned to PI3K pathway dependence would be required to drive adoption; the historical record does not show an established, definitive label population. [2], [3]
-
What is the biggest driver of upside in a market scenario?
Demonstrated superiority in efficacy within a defined biomarker population with manageable tolerability versus standard PI3K pathway options. [2], [3]
References
[1] Drugs.com. (n.d.). Taselisib (GDC-0032) / PI3K inhibitor. https://www.drugs.com/
[2] ClinicalTrials.gov. (n.d.). Taselisib (GDC-0032) studies and results records. https://clinicaltrials.gov/
[3] PubMed. (n.d.). Taselisib (GDC-0032) clinical publications and safety/efficacy reports. https://pubmed.ncbi.nlm.nih.gov/
